Crossmark

The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact

Crossref DOI link: https://doi.org/10.1038/s41431-017-0008-z

Published Online: 2017-11-20

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Lochmüller, Hanns https://orcid.org/0000-0003-2324-8001
Torrent i Farnell, Josep

Le Cam, Yann

Jonker, Anneliene H

Lau, Lilian PL https://orcid.org/0000-0001-8407-3861
Baynam, Gareth

Kaufmann, Petra

Dawkins, Hugh JS

Lasko, Paul https://orcid.org/0000-0002-4037-3501
Austin, Christopher P

Boycott, Kym M
License Information

Text and Data Mining valid from 2017-11-20
More Information

Article History

Received: 27 April 2017

Revised: 3 August 2017

Accepted: 23 August 2017

First Online: 20 November 2017

Compliance with ethical standards

:

: This work and the IRDiRC Scientific Secretariat are supported by the European FP7 contract, “SUPPORT-IRDiRC” (N305207). H.L. receives funding from the European Commission under FP7 through NeurOmics (N305121) and RD-Connect (N305444). C.P.A. contributed to this work in his capacity as Chair of the IRDiRC Consortium Assembly, not as Director of the NCATS. The remaining authors declare that they have no competing interests.